Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Follitropin Beta→

Follitropin Beta PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
150490-85-0
Molecular formula
C538H834N148O164S13
Molecular weight
~30000 g/mol
Drug class
Recombinant human follicle-stimulating hormone (FSH) gonadotropin
Mechanism of action
Activates FSH receptors on ovarian granulosa cells to stimulate follicular growth and development. In male fertility regimens, FSH receptor activation on Sertoli cells supports spermatogenesis when used with human chorionic gonadotropin.
Indications / reported uses
  • Controlled ovarian stimulation to develop multiple follicles in women undergoing assisted reproductive technology
  • Induction of ovulation in selected women with anovulatory infertility
  • Stimulation of spermatogenesis in selected men with hypogonadotropic hypogonadism when used with hCG; product-specific criteria apply

Sources: EMA EPAR — Puregon (follitropin beta) · US DailyMed — Follitropin beta · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Recombinant human follicle-stimulating hormone (FSH) gonadotropin

Mechanism of action

Activates FSH receptors on ovarian granulosa cells to stimulate follicular growth and development. In male fertility regimens, FSH receptor activation on Sertoli cells supports spermatogenesis when used with human chorionic gonadotropin.

General use cases

  • Controlled ovarian stimulation to develop multiple follicles in women undergoing assisted reproductive technology
  • Induction of ovulation in selected women with anovulatory infertility
  • Stimulation of spermatogenesis in selected men with hypogonadotropic hypogonadism when used with hCG; product-specific criteria apply

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Follitropin Beta PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Follitropin Beta Permitted Daily Exposure (PDE) report (the Follitropin Beta PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Follitropin Beta Occupational Exposure Limit (OEL) report (the Follitropin Beta OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.